Specimen:
Collect
- One SST
Also Acceptable:
- One Green Top (Li Heparin)
- One Green Top (Na Heparin)
- One Lavender (EDTA)
- One Pink Top (EDTA)
- One Red Top
Submit
- 1 mL (Min:0.5 mL) Serum . Submit Refrigerated. Submit in a Standard Transport Tube.
Also Acceptable:
- 1 mL (Min:0.5 mL) Plasma . Submit Refrigerated. Submit in a Standard Transport Tube.
Special Handling
- Allow specimen to clot completely at room temperature
- Avoid Repeated Freeze/Thaw Cycles
- For patients receiving therapy with high biotin doses (>5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
- Separate from cells ASAP
Stability
Ambient: 5 Day(s); Refrigerated: 14 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable
Methodology
- Electrochemiluminescence Immunoassay (ECLIA)
Performed
Mon-Fri
Reported
1-3 Day(s)
CPT Codes
- 86301
Interpretive Data
General Reference Range : 0-37.0 U/mL
The Roche e801 CA 19-9 electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. CA 19-9 is useful in monitoring pancreatic, hepatobiliary, gastric, hepatocellular, and colorectal cancer. The CA 19-9 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
The Roche e801 CA 19-9 electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. CA 19-9 is useful in monitoring pancreatic, hepatobiliary, gastric, hepatocellular, and colorectal cancer. The CA 19-9 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Components
- 5019 - CA 19-9
Last Updated: January 20, 2025 @ 10:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
